. |
| 
|  | Juny 2013 | 
|
|---|
dl | dm | dc | dj | dv | ds | dg |
| | | | | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | |
|
| 
|
NCI Benchmarks |  |
Staudt elected to National Academy of Sciences
Louis Staudt, M.D., Ph.D., is the deputy chief of the Metabolism Branch in NCI’s Center for Cancer Research. In this video from March 2012, Staudt discusses the basic biology of targeted therapy for Diffuse B-cell Lymphoma and about ibrutinib, a drug with a high degree of efficacy—and only modest side effects—in the treatment of the ABC form of Diffuse B-cell Lymphoma.
A New Delivery for Cancer Drugs
The protein tumor necrosis factor-alpha (TNF-alpha) is a powerful weapon in the arsenal to control cancer. Unfortunately, as is the case with many potent cancer therapies, the use of TNF-alpha as an anti-cancer therapy has been severely limited. “It was so toxic that it caused death,” and researchers gave up on it, explains Scott [...]
Anuradha Budhu
Anuradha Budhu, Ph.D., heads a research team at the National Cancer Institute that recently uncovered an imbalance between saturated and unsaturated fats (such as palmitic or fatty acids) that occur in patients with a common liver cancer called hepatocellular carcinoma, or HCC. Budhu’s team also determined that HCC patients with high unsaturated fat levels had [...]
 EurekAlert! - Cancer | |
Ibrutinib continues strong showing against mantle cell lymphoma
(University of Texas M. D. Anderson Cancer Center) In a major international study led by researchers at the University of Texas MD Anderson Cancer Center, the targeted therapy ibrutinib continues to show remarkable promise for the treatment of relapsed or refractory mantle cell lymphoma.
Scientists awarded $1.4 million to develop new therapeutic approaches to chronic leukemia
(Scripps Research Institute) Scientists from the Florida campus of The Scripps Research Institute have been awarded more than $1.4 million from the National Cancer Institute of the National Institutes of Health to create a potential new drug to attack the malignant cells that cause chronic lymphocytic leukemia, the most common leukemia in the Western world.
Genetics of cervical cancer raise concern about antiviral therapy in some cases
(Oregon State University) A new understanding of the genetic process that can lead to cervical cancer may help improve diagnosis of potentially dangerous lesions for some women, and also raises a warning flag about the use of anti-viral therapies in certain cases -- suggesting they could actually trigger the cancer they are trying to cure.
|
|
. |
Noticies recents:
25-02-2013
06-02-2013
20-11-2012
09-11-2012
03-10-2012
30-09-2012 Or per combatre el càncer Els nanotecnòlegs investiguen com fer servir partícules minúscules del metall més preciós per tractar de manera més efectiva els càncers més agressius |
17-09-2012
14-09-2012
11-09-2012
10-09-2012
07-09-2012
06-09-2012
06-09-2012
06-09-2012
05-09-2012
05-09-2012
05-09-2012
03-09-2012 Fototermia i quimio contra melanoma i glioma Un nou nanofàrmac que combina fototèrmia i quimioteràpia per la lluita contra el càncer resulta prometedor per als tractaments del càncer de pell (melanomes) i per als tumors no sòlids del sistema nerviós com els gliomes |
31-08-2012
14-08-2012
| . |
